| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Aug 16, 2024 | Sale | $75.08 | 18,714 | 1,405,047 | 29,700 | Aug 20, 2024, 06:03 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Aug 16, 2024 | Option Exercise | $36.89 | 18,714 | 690,359 | 48,414 | Aug 20, 2024, 06:03 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Mar 07, 2024 | Sale | $66.57 | 13,132 | 874,179 | 34,196 | Mar 11, 2024, 08:31 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Mar 11, 2024 | Sale | $65.61 | 7,345 | 481,931 | 32,742 | Mar 11, 2024, 08:31 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Feb 26, 2024 | Sale | $70.13 | 7,907 | 554,491 | 37,407 | Feb 27, 2024, 07:58 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Feb 02, 2024 | Sale | $67.15 | 11,860 | 796,367 | 36,604 | Feb 05, 2024, 06:07 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Nov 06, 2023 | Option Exercise | $23.94 | 26,754 | 640,491 | 72,093 | Nov 08, 2023, 05:31 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Nov 06, 2023 | Sale | $55.63 | 42,393 | 2,358,152 | 45,339 | Nov 08, 2023, 05:31 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Aug 07, 2023 | Option Exercise | $18.59 | 55,300 | 1,028,027 | 100,639 | Aug 09, 2023, 06:05 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Aug 07, 2023 | Sale | $58.79 | 55,300 | 3,251,087 | 45,339 | Aug 09, 2023, 06:05 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Mar 28, 2023 | Sale | $54.31 | 15,604 | 847,380 | 55,522 | Mar 30, 2023, 05:08 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Mar 10, 2023 | Sale | $43.34 | 8,550 | 370,557 | 59,157 | Mar 13, 2023, 07:35 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Mar 13, 2023 | Sale | $44.98 | 3,758 | 169,042 | 61,366 | Mar 13, 2023, 07:35 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Mar 01, 2023 | Sale | $50.01 | 7,241 | 362,122 | 49,199 | Mar 03, 2023, 07:03 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Feb 24, 2023 | Sale | $47.12 | 4,046 | 190,648 | 56,440 | Feb 27, 2023, 08:03 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Feb 21, 2023 | Sale | $47.01 | 3,898 | 183,246 | 53,338 | Feb 22, 2023, 08:05 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Apr 08, 2022 | Sale | $64.37 | 86,348 | 5,558,051 | 114,211 | Apr 08, 2022, 06:56 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Apr 08, 2022 | Option Exercise | $12.73 | 86,348 | 1,099,210 | 131,687 | Apr 08, 2022, 06:56 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Feb 24, 2022 | Sale | $52.21 | 7,906 | 412,810 | 50,585 | Feb 25, 2022, 07:08 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Feb 22, 2022 | Sale | $55.29 | 11,139 | 615,827 | 49,946 | Feb 23, 2022, 07:07 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Jan 10, 2022 | Sale | $40.78 | 20,948 | 854,255 | 63,526 | Jan 11, 2022, 08:06 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Oct 18, 2021 | Sale | $40.86 | 13,448 | 549,551 | 52,085 | Oct 19, 2021, 04:26 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Feb 19, 2021 | Sale | $39.22 | 5,184 | 203,308 | 45,939 | Feb 22, 2021, 08:07 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Jan 11, 2021 | Sale | $32.02 | 9,684 | 310,082 | 39,384 | Jan 12, 2021, 07:06 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Oct 16, 2020 | Sale | $26.80 | 6,792 | 182,026 | 28,120 | Oct 16, 2020, 04:04 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Jan 08, 2020 | Option Exercise | $26.34 | 6,157 | 162,175 | 21,464 | Jan 10, 2020, 09:11 PM | |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | Oct 16, 2019 | Sale | $8.25 | 6,774 | 55,886 | 6,674 | Oct 17, 2019, 04:50 PM |
Menu